ABSTRACT
Objectives To characterize the clinical severity of COVID-19 caused by Omicron, Delta, and Alpha SARS-CoV-2 variants among hospitalized adults and to compare the effectiveness of mRNA COVID-19 vaccines to prevent hospitalizations caused by each variant.
Design A case-control study of 11,690 hospitalized adults.
Setting Twenty-one hospitals across the United States.
Participants This study included 5728 cases hospitalized with COVID-19 and 5962 controls hospitalized without COVID-19. Cases were classified into SARS-CoV-2 variant groups based on viral whole genome sequencing, and if sequencing did not reveal a lineage, by the predominant circulating variant at the time of hospital admission: Alpha (March 11 to July 3, 2021), Delta (July 4 to December 25, 2021), and Omicron (December 26, 2021 to January 14, 2022).
Main Outcome Measures Vaccine effectiveness was calculated using a test-negative design for COVID-19 mRNA vaccines to prevent COVID-19 hospitalizations by each variant (Alpha, Delta, Omicron). Among hospitalized patients with COVID-19, disease severity on the WHO Clinical Progression Ordinal Scale was compared among variants using proportional odds regression.
Results Vaccine effectiveness of the mRNA vaccines to prevent COVID-19-associated hospitalizations included: 85% (95% CI: 82 to 88%) for 2 vaccine doses against Alpha; 85% (95% CI: 83 to 87%) for 2 doses against Delta; 94% (95% CI: 92 to 95%) for 3 doses against Delta; 65% (95% CI: 51 to 75%) for 2 doses against Omicron; and 86% (95% CI: 77 to 91%) for 3 doses against Omicron. Among hospitalized unvaccinated COVID-19 patients, severity on the WHO Clinical Progression Scale was higher for Delta than Alpha (adjusted proportional odds ratio [aPOR] 1.28, 95% CI: 1.11 to 1.46), and lower for Omicron than Delta (aPOR 0.61, 95% CI: 0.49 to 0.77). Compared to unvaccinated cases, severity was lower for vaccinated cases for each variant, including Alpha (aPOR 0.33, 95% CI: 0.23 to 0.49), Delta (aPOR 0.44, 95% CI: 0.37 to 0.51), and Omicron (aPOR 0.61, 95% CI: 0.44 to 0.85).
Conclusions mRNA vaccines were highly effective in preventing COVID-19-associated hospitalizations from Alpha, Delta, and Omicron variants, but three vaccine doses were required to achieve protection against Omicron similar to the protection that two doses provided against Delta and Alpha. Among adults hospitalized with COVID-19, Omicron caused less severe disease than Delta, but still resulted in substantial morbidity and mortality. Vaccinated patients hospitalized with COVID-19 had significantly lower disease severity than unvaccinated patients for all the variants.
Competing Interest Statement
Competing Interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. The following declarations have been made. Adam S. Lauring reports consultant fees from Sanofi and fees from Roche for membership on a trial steering committee. James D. Chappell reports grant support from CDC and NIH. Manjusha Gaglani reports grant support from CDC. Adit A. Ginde reports grant support from CDC, NIH, DOD, and investigator-initiated grant support from AbbVie and Faron Pharmaceuticals. H. Keipp Talbot reports a grant from CDC. Jonathan D. Casey reports a grant (K23HL153584) from the National Institutes of Health (NIH). D. Clark Files reports consultant fees from Cytovale and membership on a Medpace Data Safety Monitoring Board (DSMB). David N. Hager reports a contract from CDC (via subcontract with VUMC) and salary support from Incyte Corporation, EMPACT Precision Medicine, and the Marcus Foundation. Matthew C. Exline reports talks on nutrition in COVID pneumonia at ASPEN conference sponsored by Abbott Labs. Michelle N. Gong reports grant support from CDC, funding from NHLBI, and fees for participating on a DSMB for Regeneron. Ithan D. Peltan reports grants from CDC, NIH, Intermountain Research and Medical Foundation, and Janssen Pharmaceuticals, institutional fees from Asahi Kasei Pharma and from Regeneron. Samuel M. Brown reports grants from CDC, Sedana, Janssen, NIH, and the Department of Defense (DOD), fees from Hamilton for chairing a DSMB; institutional fees from Faron, book royalties from Oxford University and Brigham Young University, and personal fees from New York University for service on a DSMB. Emily T. Martin reports a grant from Merck for unrelated work. Akram Khan reports grants from Gilead, Ely Lily, United Therapeutics, Johnson & Johnson (Actelion), Liquidia Pharmaceuticals, and 4D Medical. Steven Y. Chang was a speaker for La Jolla Pharmaceuticals and a Consultant for PureTech Health. Jennie H. Kwon reports grant support from NIH/NIAID (1K23 AI137321-01A1). Natasha Halasa reports grants from CDC, Sanofi and Quidel. Carlos G. Grijalva reports consultant fees from Pfizer, Merck, and Sanofi-Pasteur and grants from Campbell Alliance/Syneos Health, CDC, NIH, FDA, AHRQ, and Sanofi. Todd Rice reports grant support from CDC. Christopher J. Lindsell reports grants from CDC, NIH, DoD, and the Marcus Foundation, organizational contract fees from bioMerieux, Endpoint LLC, and Entegrion, Inc., and a patent issued to Cincinnati Childrens Hospital Medical Center for risk stratification in sepsis and septic shock. Wesley H. Self reports grant funding from CDC for this work, grants and consultant fees from Merck outside this work and consultant fees from Aerpio Pharmaceuticals outside this work. No other potential conflicts of interest were disclosed.
Funding Statement
Primary funding for this study was provided by the US Centers for Disease Control and Prevention (award 75D30121F00002 to Dr. Self). Scientists from the US CDC participating in all aspects of this study, including its design, analysis, interpretation of data, writing the report, and the decision to submit the article for publication. The REDCap data tool used in this study was supported by a Clinical and Translational Science Award (UL1 TR002243) from the National Center for Advancing Translational Sciences, National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This program was approved as a public health surveillance activity with waiver of informed consent by institutional review boards at the US Centers for Disease Control and Prevention (CDC), the program coordinating center at Vanderbilt University Medical Center and each participating site. The institutional review boards at the US Centers for Disease Control and Prevention and Vanderbilt University Medical Center waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** A full list of investigators and collaborators in the Influenza and other Viruses in the Acutely Ill (IVY) Network is available in the Supplementary Appendix.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.
Data Availability
Additional data produced in this work are not available.
